I 
118TH CONGRESS 
1ST SESSION H. R. 3703 
To direct the Comptroller General of the United States to conduct and 
complete a review examining the efforts of the Secretary of Health 
and Human Services to ensure that the United States is prepared to 
rapidly produce certain medical countermeasures in the event of a public 
health emergency, and for other purposes. 
IN THE HOUSE OF REPRESENTATIVES 
MAY 25, 2023 
Mr. LATTA (for himself and Ms. KELLY of Illinois) introduced the following 
bill; which was referred to the Committee on Energy and Commerce 
A BILL 
To direct the Comptroller General of the United States to 
conduct and complete a review examining the efforts 
of the Secretary of Health and Human Services to ensure 
that the United States is prepared to rapidly produce 
certain medical countermeasures in the event of a public 
health emergency, and for other purposes. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Helping Evaluate Ap-
propriate Logistical Infrastructure for National Govern-
VerDate Sep 11 2014 
04:19 Jun 17, 2023
Jkt 039200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H3703.IH
H3703
pbinns on DSKJLVW7X2PROD with $$_JOB
ment Response Act of 2023’’ or the ‘‘HEALING Response 
Act of 2023’’. 
SEC. 2. GAO REVIEW OF HHS EFFORTS TO ENSURE RAPID 
PRODUCTION OF CERTAIN MEDICAL COUN-
TERMEASURES 
IN 
CASE 
OF 
A 
PUBLIC 
HEALTH EMERGENCY. 
(a) IN GENERAL.—Not later than 1 year after the 
date of the enactment of this Act, the Comptroller General 
of the United States shall conduct and complete a review 
examining the efforts of the Secretary of Health and 
Human Services to ensure that the United States is pre-
pared to rapidly produce qualified countermeasures (as de-
fined in section 319F–1 of the Public Health Service Act 
(42 U.S.C. 247d–6a)) in the event of a public health emer-
gency declared under section 319 of the Public Health 
Service Act (42 U.S.C. 274d). 
(b) CONTENTS.—The review conducted under sub-
section (a) shall include a review of— 
(1) the efforts described in such subsection, in-
cluding the Secretary’s efforts to transition from the 
Centers for Innovation and Advanced Drug Manu-
facturing program to any new efforts, including the 
National Biopharmaceutical Manufacturing Partner-
ship and Industrial Base Expansion Connect; 
VerDate Sep 11 2014 
04:19 Jun 17, 2023
Jkt 039200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H3703.IH
H3703
pbinns on DSKJLVW7X2PROD with $$_JOB
(2) the progress made toward the implementa-
tion of such efforts; and 
(3) the planning within the Department of 
Health and Human Services to assess risks and 
challenges associated with advanced development 
and manufacturing of qualified countermeasures. 
(c) REPORT TO CONGRESS.—Not later than 1 year 
after completing the review under subsection (a), the 
Comptroller General of the United States shall submit to 
the Congress a report containing— 
(1) the results of the review; and 
(2) the Comptroller General’s recommendations 
for ensuring that the United States is prepared to 
rapidly produce qualified countermeasures in the 
event of a public health emergency. 
Æ 
VerDate Sep 11 2014 
04:19 Jun 17, 2023
Jkt 039200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6301
E:\BILLS\H3703.IH
H3703
pbinns on DSKJLVW7X2PROD with $$_JOB